European Pharmaceutical Review

FEBRUARY 14, 2023

Recently there have been several key advances in the clinical development of messenger RNA (mRNA) vaccines, including vaccines for RSV and a personalised cancer vaccine. Sarah Bundra, Pharmaceutical Analyst at GlobalData also warned about patient safety: “introducing mRNA carries the risk of activating the immune system.”

Vaccines 105

Vaccines Immunization FDA 105

European Pharmaceutical Review

DECEMBER 1, 2022

According to GlobalData’s recent report , a total of five marketed messenger RNA (mRNA) non-vaccine products by 2028 will generate over $2 billion, generated by the approval of pipeline agents. The post mRNA non-vaccine therapeutics to generate $2 billion by 2028 appeared first on European Pharmaceutical Review.

Vaccines 98

Vaccines Immunization 98

European Pharmaceutical Review

SEPTEMBER 1, 2023

At the end of August 2023, BioNTech announced that the Committee for Medicinal Products for Human Use (CHMP) had recommended its adapted Comirnaty mRNA-based vaccine for regulatory approval as preventive treatment against the COVID-19 Omicron XBB.1.5 subvariant. percent of the total mRNA therapy market by 2029.

Immunization 110

Immunization Vaccines 110

European Pharmaceutical Review

SEPTEMBER 22, 2023

Active anti-Abeta immunotherapies In the 2000s, the concept of active immunotherapy targeting Abeta in Alzheimer’s patients was assessed with the ELAN vaccine (AN1792), consisting of full-length aggregated Abeta 1-42 peptide mixed with the QS21 adjuvant. 8 However, as this trial was not placebo-controlled, conclusions are difficult to draw.

Immunization 97

Immunization Vaccines Communication Labelling 97

The Checkup by Singlecare

NOVEMBER 30, 2023

Acetaminophen may also blunt the effects of other medications that impact the immune system, including some medicines used to manage cancer diagnoses and even the immune response following vaccinations. However, after vaccine administration, ACIP recommends use for fever treatment and local pain.

Immunization 98

Immunization Vaccines FDA Labelling 98

PharmaShots

APRIL 25, 2023

Through its internal development, partnerships, and acquisitions, the company has put together four technology platforms that primarily focus on antibodies, T cells, innate immunity, and siRNAs. R&D Expenditure: $883M Founded Year: 2002 Total Employees: ~2000 Headquarters: Massachusetts, United States Market Cap: $25.4B

HIV Treatment and Prevention Agents 40

HIV Treatment and Prevention Agents Packaging Immunization Vaccines 40

pharmaphorum

DECEMBER 15, 2022

Stefan Woxström is the new senior vice president for Europe and Canada at AstraZeneca, moving over from the company’s Japanese division to take over from Iskra Reic , who will now serve as EVP of vaccines and immune therapies. Diaz has been with Almirall since 2002, most recently serving as senior director of corporate strategy.

Immunization 52

Immunization Vaccines 52